MUSTANG BIO, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
MUSTANG BIO, INC. (MBIO) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $861.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2025-03-28
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-12-31 was $477.00K, a 66.74% decline year-over-year.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-09-30 was $50.00K, a 25.00% increase year-over-year.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-12-31 was $1.43M, a 65.95% decline year-over-year.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-09-30 was $40.00K, a 93.65% decline year-over-year.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $861.00K, a 63.38% increase from fiscal 2023.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $527.00K, a 64.25% decline from fiscal 2022.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $1.47M, a 74.77% decline from fiscal 2021.
- MUSTANG BIO, INC. research and development asset acquired other than through business combination, written-off for fiscal 2021 was $5.84M, a 41.95% decline from fiscal 2020.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 7 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 10 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $861.00K 10-K · filed 2025-03-28 | ||||||
| 2023-12-31 | $477.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $527.00K derived: sum of 2 quarters · filed 2025-03-28 | $527.00K 10-K · filed 2025-03-28 | ||||
| 2023-09-30 | $50.00K 10-Q · filed 2023-11-14 | $50.00K 10-Q · filed 2023-11-14 | |||||
| 2022-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $1.47M derived: sum of 2 quarters · filed 2024-03-11 | $1.47M 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | $40.00K 10-Q · filed 2023-11-14 | $40.00K 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | ||||||
| 2021-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $4.84M derived: sum of 2 quarters · filed 2023-03-30 | $5.84M derived: sum of 3 quarters · filed 2023-03-30 | $5.84M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $630.00K 10-Q · filed 2022-11-14 | $1.63M derived: sum of 2 quarters · filed 2022-11-14 | $1.63M 10-Q · filed 2022-11-14 | $9.86M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-11 | $1.00M 10-Q · filed 2022-08-11 | $9.23M derived: sum of 3 quarters · filed 2022-08-11 | $9.51M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-14 | $8.23M derived: sum of 2 quarters · filed 2022-03-23 | $8.51M derived: sum of 3 quarters · filed 2022-03-23 | $9.81M derived: sum of 4 quarters · filed 2022-03-23 | |||
| 2020-12-31 | $8.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $8.51M derived: sum of 2 quarters · filed 2022-03-23 | $9.81M derived: sum of 3 quarters · filed 2022-03-23 | $10.06M 10-K · filed 2022-03-23 | |||
| 2020-09-30 | $287.00K 10-Q · filed 2021-11-12 | $1.59M derived: sum of 2 quarters · filed 2021-11-12 | $1.84M 10-Q · filed 2021-11-12 | $6.76M derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $1.30M 10-Q · filed 2021-08-16 | $1.55M 10-Q · filed 2021-08-16 | $6.47M derived: sum of 3 quarters · filed 2021-08-16 | $7.17M derived: sum of 4 quarters · filed 2021-08-16 | |||
| 2020-03-31 | $250.00K 10-Q · filed 2021-05-14 | $5.17M derived: sum of 2 quarters · filed 2021-05-14 | $5.87M derived: sum of 3 quarters · filed 2021-05-14 | $6.07M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $5.62M derived: sum of 2 quarters · filed 2021-03-24 | $5.82M derived: sum of 3 quarters · filed 2021-03-24 | $6.27M 10-K · filed 2021-03-24 | |||
| 2019-09-30 | $700.00K 10-Q · filed 2020-11-06 | $900.00K derived: sum of 2 quarters · filed 2020-11-06 | $1.35M 10-Q · filed 2020-11-06 | $3.63M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-10 | $650.00K 10-Q · filed 2020-08-10 | $2.94M derived: sum of 3 quarters · filed 2020-08-10 | $3.94M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $450.00K 10-Q · filed 2020-05-11 | $2.73M derived: sum of 2 quarters · filed 2020-05-11 | $3.73M derived: sum of 3 quarters · filed 2020-05-11 | $3.73M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $3.29M derived: sum of 2 quarters · filed 2020-03-16 | $3.29M derived: sum of 3 quarters · filed 2020-03-16 | $3.36M 10-K · filed 2020-03-16 | $1.27M 10-K · filed 2019-03-18 | ||
| 2018-09-30 | $1.00M 10-Q · filed 2019-11-12 | $1.00M derived: sum of 2 quarters · filed 2019-11-12 | $1.07M 10-Q · filed 2019-11-12 | $1.57M derived: sum of 4 quarters · filed 2019-11-12 | |||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $75.00K 10-Q · filed 2018-08-13 | $575.00K derived: sum of 3 quarters · filed 2019-03-18 | $875.00K derived: sum of 4 quarters · filed 2019-03-18 | |||
| 2018-03-31 | $75.00K 10-Q · filed 2018-05-14 | $575.00K derived: sum of 2 quarters · filed 2019-03-18 | $875.00K derived: sum of 3 quarters · filed 2019-03-18 | $2.38M derived: sum of 4 quarters · filed 2019-03-18 | |||
| 2017-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $800.00K derived: sum of 2 quarters · filed 2019-03-18 | $2.30M derived: sum of 3 quarters · filed 2019-03-18 | $2.88M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $1.80M derived: sum of 2 quarters · filed 2018-11-13 | $2.38M 10-Q · filed 2018-11-13 | $2.38M derived: sum of 4 quarters · filed 2018-11-13 | |||
| 2017-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $2.08M 10-Q · filed 2018-08-13 | $2.08M derived: sum of 3 quarters · filed 2018-08-13 | $2.08M derived: sum of 4 quarters · filed 2018-08-13 | |||
| 2017-03-31 | $575.00K 10-Q · filed 2018-05-14 | $575.00K derived: sum of 2 quarters · filed 2018-05-14 | $575.00K derived: sum of 3 quarters · filed 2018-05-14 | $575.00K derived: sum of 4 quarters · filed 2018-05-14 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 derived: sum of 2 quarters · filed 2018-03-29 | $0.00 derived: sum of 3 quarters · filed 2018-03-29 | $0.00 10-K · filed 2018-03-29 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | ||||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | |||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-15 | ||||||
| 2015-12-31 | $2.00M 10-K · filed 2018-03-29 | ||||||
| 2015-09-30 | $2.00M 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |